Modern Diagnostic & Research Centre Ltd (MDRCL) — shareholding pattern, promoter holding, financials and share price
About Modern Diagnostic & Research Centre Ltd (MDRCL)
Modern Diagnostic & Research Centre Ltd operates in the Healthcare Service Provider industry, within the Healthcare sector. It trades on the NSE as MDRCL and on the BSE under scrip code 544673. Its ISIN is INE1HK501016.
Incorporated in 1985, Modern Diagnostic & Research Centre Limited (MDRC) is a diagnostic chain in India, offering a comprehensive range of pathology and radiology services. [1]
Listed peers in Healthcare Service Provider: Nephro Care India Ltd, Aspira Pathlab & Diagnostics Ltd, Invicta Diagnostic Ltd, Choksi Laboratories Ltd, Bandaram Pharma Packtech Ltd, N G Industries Ltd.
Valuation & Returns
10 Jul 2026At ₹52 a share on 10 Jul 2026, Modern Diagnostic & Research Centre Ltd (MDRCL) was valued at a price-to-earnings ratio of 14.96x against an industry P/E of 61.73x and a price-to-book of 1.36x on a book value of ₹38.16 per share. Solomo computes return on equity of 8.97% and return on capital employed of 8.79% from filed results.
- P/E
- 14.96x
- Industry P/E
- 61.73x
- P/B
- 1.36x
- EPS (TTM)
- ₹8.15
- Book value / share
- ₹38.16
- ROE
- 8.97%
- ROCE
- 8.79%
- ROA
- 4.43%
- Debt / equity
- 0.63x
- Dividend yield
- 0%
- EBITDA margin
- 16.38%
- 52-week range
- ₹49.5 – ₹100
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Modern Diagnostic & Research Centre Ltd (MDRCL) reported revenue of ₹83.11 crore, net profit of ₹5.25 crore and earnings per share of ₹3.48. That compares with revenue of ₹77.95 crore and net profit of ₹8.97 crore in Mar 2025. Figures are standalone, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹39.92 crore and net profit ₹2.08 crore (standalone).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 60.21 | 56.28 | 67.13 | 77.95 | 83.11 |
| Net profit (₹ cr) | -1.45 | -5.73 | 5.79 | 8.97 | 5.25 |
| EPS (₹) | -14.5 | -57.3 | 57.9 | 8.15 | 3.48 |
| Measure | 3Y | 1Y |
|---|---|---|
| Sales growth | 8.99% | 16.12% |
| Profit growth | - | 54.92% |
Ownership Summary
Mar 2026As of Mar 2026, promoters hold 72.85% of Modern Diagnostic & Research Centre Ltd (MDRCL), foreign institutional investors (FII) hold 0.03% and domestic institutional investors (DII) hold 15.48%. Market capitalisation was ₹79 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Mar 2026.
Largest disclosed public shareholders in Mar 2026: Aarth Aif Growth Fund 4.48%, Nexus Equity Growth Fund - Nexus Equity Growth Fund Sch-1 2.05%, Sb Opportunities Fund II 1.93%, Sunrise Investment Trust- Sunrise Investment Opportunities Fund 1.67%, Affluence Gems Private Limited 1.52%, Srinivasa Vara Prasad Yagnamurthy Chenchu 1.48%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Mar 2026 | 72.85% | - | 0.03% | 15.48% | 27.15% |